Switch theme
Sign up to access all valuation multiples
Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company follows drugs on already approved biological drugs that can be introduced at a lower price after the patent expires on the original drug. The company has a patented protein production platform with greater productivity than standard systems for producing proteins in E.coli host cells. Xbrane’s product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration.
2008
65
LTM Revenue $42.2M
LTM EBITDA $7.8M
$49.9M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Xbrane Biopharma has a last 12-month revenue (LTM) of $42.2M and a last 12-month EBITDA of $7.8M.
In the most recent fiscal year, Xbrane Biopharma achieved revenue of $20.8M and an EBITDA of -$19.2M.
Xbrane Biopharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Xbrane Biopharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $42.2M | XXX | $20.8M | XXX | XXX | XXX |
| Gross Profit | $35.9M | XXX | $18.9M | XXX | XXX | XXX |
| Gross Margin | 85% | XXX | 91% | XXX | XXX | XXX |
| EBITDA | $7.8M | XXX | -$19.2M | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | -93% | XXX | XXX | XXX |
| EBIT | $6.5M | XXX | -$22.9M | XXX | XXX | XXX |
| EBIT Margin | 15% | XXX | -110% | XXX | XXX | XXX |
| Net Profit | $0.5M | XXX | -$27.9M | XXX | XXX | XXX |
| Net Margin | 1% | XXX | -134% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $2.6M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 14, 2025, Xbrane Biopharma's stock price is SEK 0 (or $0).
Xbrane Biopharma has current market cap of SEK 352M (or $36.8M), and EV of SEK 477M (or $49.9M).
See Xbrane Biopharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $49.9M | $36.8M | XXX | XXX | XXX | XXX | $-0.00 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 14, 2025, Xbrane Biopharma has market cap of $36.8M and EV of $49.9M.
Xbrane Biopharma's trades at 2.4x EV/Revenue multiple, and -2.6x EV/EBITDA.
Equity research analysts estimate Xbrane Biopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Xbrane Biopharma has a P/E ratio of 70.1x.
See valuation multiples for Xbrane Biopharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $36.8M | XXX | $36.8M | XXX | XXX | XXX |
| EV (current) | $49.9M | XXX | $49.9M | XXX | XXX | XXX |
| EV/Revenue | 1.2x | XXX | 2.4x | XXX | XXX | XXX |
| EV/EBITDA | 6.4x | XXX | -2.6x | XXX | XXX | XXX |
| EV/EBIT | 7.6x | XXX | -2.2x | XXX | XXX | XXX |
| EV/Gross Profit | 1.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | 70.1x | XXX | -1.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -2.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialXbrane Biopharma's last 12 month revenue growth is 18%
Xbrane Biopharma's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.6M for the same period.
Xbrane Biopharma's rule of 40 is -109% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Xbrane Biopharma's rule of X is 63% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Xbrane Biopharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 18% | XXX | 39% | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | -93% | XXX | XXX | XXX |
| EBITDA Growth | 245% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -109% | XXX | -75% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 63% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 157% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 201% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Xbrane Biopharma acquired XXX companies to date.
Last acquisition by Xbrane Biopharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Xbrane Biopharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Xbrane Biopharma founded? | Xbrane Biopharma was founded in 2008. |
| Where is Xbrane Biopharma headquartered? | Xbrane Biopharma is headquartered in Sweden. |
| How many employees does Xbrane Biopharma have? | As of today, Xbrane Biopharma has 65 employees. |
| Who is the CEO of Xbrane Biopharma? | Xbrane Biopharma's CEO is Mr. Martin Amark. |
| Is Xbrane Biopharma publicy listed? | Yes, Xbrane Biopharma is a public company listed on STO. |
| What is the stock symbol of Xbrane Biopharma? | Xbrane Biopharma trades under XBRANE ticker. |
| When did Xbrane Biopharma go public? | Xbrane Biopharma went public in 2016. |
| Who are competitors of Xbrane Biopharma? | Similar companies to Xbrane Biopharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Xbrane Biopharma? | Xbrane Biopharma's current market cap is $36.8M |
| What is the current revenue of Xbrane Biopharma? | Xbrane Biopharma's last 12 months revenue is $42.2M. |
| What is the current revenue growth of Xbrane Biopharma? | Xbrane Biopharma revenue growth (NTM/LTM) is 18%. |
| What is the current EV/Revenue multiple of Xbrane Biopharma? | Current revenue multiple of Xbrane Biopharma is 1.2x. |
| Is Xbrane Biopharma profitable? | Yes, Xbrane Biopharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Xbrane Biopharma? | Xbrane Biopharma's last 12 months EBITDA is $7.8M. |
| What is Xbrane Biopharma's EBITDA margin? | Xbrane Biopharma's last 12 months EBITDA margin is 19%. |
| What is the current EV/EBITDA multiple of Xbrane Biopharma? | Current EBITDA multiple of Xbrane Biopharma is 6.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
